

EXHIBIT 7

To: Calico LLC (tmdocketing@google.com)

Subject: U.S. TRADEMARK APPLICATION NO. 86220187 - CALICO - N/A

Sent: 1/20/2015 11:59:08 AM

Sent As: ECOM115@USPTO.GOV

Attachments: [Attachment - 1](#)
[Attachment - 2](#)
[Attachment - 3](#)
[Attachment - 4](#)
[Attachment - 5](#)
[Attachment - 6](#)
[Attachment - 7](#)
[Attachment - 8](#)
[Attachment - 9](#)
[Attachment - 10](#)
[Attachment - 11](#)
[Attachment - 12](#)
[Attachment - 13](#)
[Attachment - 14](#)
[Attachment - 15](#)
[Attachment - 16](#)
[Attachment - 17](#)
[Attachment - 18](#)
[Attachment - 19](#)
[Attachment - 20](#)
[Attachment - 21](#)
[Attachment - 22](#)
[Attachment - 23](#)
[Attachment - 24](#)
[Attachment - 25](#)
[Attachment - 26](#)
[Attachment - 27](#)
[Attachment - 28](#)
[Attachment - 29](#)
[Attachment - 30](#)
[Attachment - 31](#)
[Attachment - 32](#)
[Attachment - 33](#)
[Attachment - 34](#)
[Attachment - 35](#)

[Attachment - 36](#)

[Attachment - 37](#)

[Attachment - 38](#)

[Attachment - 39](#)

[Attachment - 40](#)

[Attachment - 41](#)

[Attachment - 42](#)

[Attachment - 43](#)

[Attachment - 44](#)

[Attachment - 45](#)

[Attachment - 46](#)

[Attachment - 47](#)

[Attachment - 48](#)

[Attachment - 49](#)

[Attachment - 50](#)

[Attachment - 51](#)

[Attachment - 52](#)

[Attachment - 53](#)

[Attachment - 54](#)

[Attachment - 55](#)

[Attachment - 56](#)

[Attachment - 57](#)

[Attachment - 58](#)

[Attachment - 59](#)

[Attachment - 60](#)

[Attachment - 61](#)

[Attachment - 62](#)

[Attachment - 63](#)

[Attachment - 64](#)

[Attachment - 65](#)

[Attachment - 66](#)

[Attachment - 67](#)

[Attachment - 68](#)

[Attachment - 69](#)

[Attachment - 70](#)

[Attachment - 71](#)

[Attachment - 72](#)

[Attachment - 73](#)

[Attachment - 74](#)

[Attachment - 75](#)

[Attachment - 76](#)

[Attachment - 77](#)
[Attachment - 78](#)
[Attachment - 79](#)
[Attachment - 80](#)
[Attachment - 81](#)
[Attachment - 82](#)
[Attachment - 83](#)
[Attachment - 84](#)
[Attachment - 85](#)

**UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO)
OFFICE ACTION (OFFICIAL LETTER) ABOUT APPLICANT'S TRADEMARK APPLICATION**

| | |
|---|---|
| U.S. APPLICATION SERIAL NO. 86220187 | |
| MARK: CALICO | *86220187* |
| CORRESPONDENT ADDRESS: MONIQUE LIBURD 1600 AMPHITHEATRE PKWY MOUNTAIN VIEW, CA 94043-1351 | CLICK HERE TO RESPOND TO THIS I http://www.uspto.gov/trademarks/teas/response VIEW YOUR APPLICATION FILE |
| APPLICANT: Calico LLC | |
| CORRESPONDENT'S REFERENCE/DOCKET NO : N/A CORRESPONDENT E-MAIL ADDRESS: tmdocketing@google.com | |

OFFICE ACTION

STRICT DEADLINE TO RESPOND TO THIS LETTER

TO AVOID ABANDONMENT OF APPLICANT'S TRADEMARK APPLICATION, THE USPTO MUST RECEIVE APPLICANT'S COMPLETE RESPONSE TO THIS LETTER **WITHIN 6 MONTHS** OF THE ISSUE/MAILING DATE BELOW.

ISSUE/MAILING DATE: 1/20/2015

THIS IS A FINAL ACTION.

This Office action is in response to applicant's communication filed on December 23, 2014.

Applicant's amended identification of goods and services and clarification regarding its entity type are **accepted** and made of record. The notation of a possible conflict with the mark in Application Serial No. 86088869 is **withdrawn**, as that application has been abandoned.

Section 2(d) - Likelihood of Confusion Refusal—FINAL

THE FOLLOWING REFUSAL APPLIES ONLY TO THE GOODS AND SERVICES SPECIFIED HEREIN:

Registration was initially refused for the goods “pharmaceutical preparations” and “medicines for the treatment of aging, immunological diseases and degenerative conditions of the body, the promotion of life extension and restoration of youthful bodily functions” in Class 5; and the services “providing medical information, consultancy, and advisory services for the treatment of aging, immunological diseases and degenerative conditions of the body, the promotion of life extension, and restoration of youthful bodily functions” in Class 44 under Trademark Action Section 2(d), 15 U.S.C. Section 1052(d), on the grounds that applicant's mark, when used on or in connection with the identified services, so resembles the mark in U.S. Registration No. 3680863 (“CALICO”) as to be likely to cause confusion, to cause mistake, or to deceive. TMEP §§1207.01 *et seq.* The cited registration was sent previously. Although the examining attorney has carefully considered applicant's arguments in support of registration, she finds them unpersuasive for the following reasons.

In light of applicant's amended identification of goods, the refusal now applies to the goods “pharmaceutical preparations, namely, pharmaceuticals for the prevention and treatment of cancer, age-related conditions, and neurodegenerative disorders such as Alzheimer's disease, dementia, amyotrophic lateral sclerosis, Friedreich's ataxia, Huntington's disease, Lewy body disease, Parkinson's disease, spinal muscular atrophy, cancer, atherosclerosis, arthritis, cataracts, osteoarthritis, and cardiovascular disease” and “medicines for the treatment of aging, immunological diseases and degenerative conditions of the body, the promotion of life extension and restoration of youthful bodily functions, namely, Alzheimer's disease, dementia, amyotrophic lateral sclerosis, Friedreich's ataxia, Huntington's disease, Lewy body disease, Parkinson's disease, spinal muscular atrophy, cancer, atherosclerosis, arthritis, cataracts, osteoarthritis, and cardiovascular disease” in Class 5; and “providing medical information, consultancy, and advisory services for the treatment of aging, immunological diseases and degenerative conditions of the body, the promotion of life extension, and restoration of youthful bodily functions” in Class 44.

As was noted previously, Trademark Act Section 2(d) bars registration of an applied-for mark that so resembles a registered mark that it is likely a potential consumer would be confused, mistaken, or deceived as to the source of the goods and services of the applicant and registrant. *See* 15 U.S.C. §1052(d). A determination of likelihood of confusion under Section 2(d) is made on a case-by case basis and the factors set forth in *In re E. I. du Pont de Nemours & Co.*, 476 F.2d 1357, 177 USPQ 563 (C.C.P.A. 1973) aid in this determination. *Citigroup Inc. v. Capital City Bank Grp., Inc.*, 637 F.3d 1344, 1349, 98 USPQ2d 1253, 1256 (Fed. Cir. 2011) (citing *On-Line Careline, Inc. v. Am. Online, Inc.*, 229 F.3d 1080, 1085, 56 USPQ2d 1471, 1474 (Fed. Cir. 2000)). Not all the *du Pont* factors, however, are necessarily relevant or of equal weight, and any one of the factors may control in a given case, depending upon the evidence of record. *Citigroup Inc. v. Capital City Bank Grp., Inc.*, 637 F.3d at 1355, 98 USPQ2d at 1260; *In re Majestic Distilling Co.*, 315 F.3d 1311, 1315, 65 USPQ2d 1201, 1204 (Fed. Cir. 2003); *see In re E. I. du Pont de Nemours & Co.*, 476 F.2d at 1361-62, 177 USPQ at 567.

In this case, the following factors are the most relevant: similarity of the marks, similarity and nature of the goods and services, and similarity of the trade channels of the goods and services. *See In re Vitterra Inc.*, 671 F.3d 1358, 1361-62, 101 USPQ2d 1905, 1908 (Fed. Cir. 2012); *In re Dakin's Miniatures Inc.* ,

59 USPQ2d 1593, 1595-96 (TTAB 1999); TMEP §§1207.01 *et seq.*

The overriding concern is not only to prevent buyer confusion as to the source of the goods and services, but to protect the registrant from adverse commercial impact due to use of a similar mark by a newcomer. *See In re Shell Oil Co.*, 992 F.2d 1204, 1208, 26 USPQ2d 1687, 1690 (Fed. Cir. 1993). Therefore, any doubt regarding a likelihood of confusion determination is resolved in favor of the registrant. TMEP §1207.01(d)(i); *see Hewlett-Packard Co. v. Packard Press, Inc.*, 281 F.3d 1261, 1265, 62 USPQ2d 1001, 1003 (Fed. Cir. 2002); *In re Hyper Shoppes (Ohio), Inc.*, 837 F.2d 463, 464-65, 6 USPQ2d 1025, 1026 (Fed. Cir. 1988).

In any likelihood of confusion determination, two key considerations are similarity of the marks and similarity or relatedness of the goods and services. *Syndicat Des Proprietaires Viticulteurs De Chateaufort-Du-Pape v. Pasquier DesVignes*, 107 USPQ2d 1930, 1938 (TTAB 2013) (citing *Federated Foods, Inc. v. Fort Howard Paper Co.*, 544 F.2d 1098, 1103, 192 USPQ 24, 29 (C.C.P.A. 1976)); *In re Iolo Techs., LLC*, 95 USPQ2d 1498, 1499 (TTAB 2010); *see* TMEP §1207.01. That is, the marks are compared in their entireties for similarities in appearance, sound, connotation, and commercial impression. *In re Viterro Inc.*, 671 F.3d 1358, 1362, 101 USPQ2d 1905, 1908 (Fed. Cir. 2012) (quoting *In re E. I. du Pont de Nemours & Co.*, 476 F.2d 1357, 1361, 177 USPQ 563, 567 (C.C.P.A. 1973)); TMEP §1207.01(b)-(b)(v). Additionally, the goods and services are compared to determine whether they are similar or commercially related or travel in the same trade channels. *See Coach Servs., Inc. v. Triumph Learning LLC*, 668 F.3d 1356, 1369-71, 101 USPQ2d 1713, 1722-23 (Fed. Cir. 2012); *Herbko Int'l, Inc. v. Kappa Books, Inc.*, 308 F.3d 1156, 1165, 64 USPQ2d 1375, 1381 (Fed. Cir. 2002); TMEP §1207.01, (a)(vi).

Identical Marks

In a likelihood of confusion determination, the marks in their entireties are compared for similarities in appearance, sound, connotation, and commercial impression. *In re E. I. du Pont de Nemours & Co.*, 476 F.2d 1357, 1361, 177 USPQ 563, 567 (C.C.P.A. 1973); TMEP §1207.01(b)-(b)(v).

In the present case, applicant's mark is "CALICO" in standard character format and the registrant's mark is "CALICO" in standard character format. Thus, the marks are identical in terms of appearance and sound. In addition, the connotation and commercial impression of the marks do not differ when considered in connection with applicant's and registrant's respective goods and services.

Therefore, the marks are confusingly similar.

Closely Related Goods and Services

First, the examining attorney notes that where the marks of the parties are identical, as is the case here, the relationship between the relevant goods and services need not be as close to support a finding of likelihood of confusion. *See In re Shell Oil Co.*, 992 F.2d 1204, 1207, 26 USPQ2d 1687, 1689 (Fed. Cir. 1993); *In re Davey Prods. Pty Ltd.*, 92 USPQ2d 1198, 1202 (TTAB 2009); *In re Thor Tech, Inc.*, 90 USPQ2d 1634, 1636 (TTAB 2009); TMEP §1207.01(a).

The goods and services of the parties need not be identical or even competitive to find a likelihood of confusion. *See On-line Careline Inc. v. Am. Online Inc.*, 229 F.3d 1080, 1086, 56 USPQ2d 1471, 1475 (Fed. Cir. 2000); *Recot, Inc. v. Becton*, 214 F.3d 1322, 1329, 54 USPQ2d 1894, 1898 (Fed. Cir. 2000) ("[E]ven if the goods in question are different from, and thus not related to, one another in kind, the same

goods can be related in the mind of the consuming public as to the origin of the goods.”); TMEP §1207.01(a)(i).

The respective goods and services need only be “related in some manner and/or if the circumstances surrounding their marketing [be] such that they could give rise to the mistaken belief that [the goods and/or services] emanate from the same source.” *Coach Servs., Inc. v. Triumph Learning LLC*, 668 F.3d 1356, 1369, 101 USPQ2d 1713, 1722 (Fed. Cir. 2012) (quoting *7-Eleven Inc. v. Wechsler*, 83 USPQ2d 1715, 1724 (TTAB 2007)); TMEP §1207.01(a)(i).

In this case, the goods and services of the parties are closely related since they all relate to pharmaceuticals and healthcare. The applicant’s goods and services at issue are various pharmaceutical preparations and medicines in Class 5, and the services “providing medical information, consultancy, and advisory services for the treatment of aging, immunological diseases and degenerative conditions of the body, the promotion of life extension, and restoration of youthful bodily functions” in Class 44.

The registrant’s services include educational services in the field of health, online magazines in the field of health, pharmaceutical advice, counseling services in the field of health and nutrition, and providing an online computer database featuring information regarding health.

Both applicant and registrant provide health information and consultancy services. As noted in the previous Office action, applicant’s services of “providing medical information, consultancy, and advisory services for the treatment of aging, immunological diseases and degenerative conditions of the body, the promotion of life extension, and restoration of youthful bodily functions” completely encompass the registrant’s services of counseling in the field of health and nutrition and providing an online computer database featuring information regarding health.

With respect to applicant’s and registrant’s services, the question of likelihood of confusion is determined based on the description of the services stated in the application and registration at issue, not on extrinsic evidence of actual use. *See Stone Lion Capital Partners, LP v. Lion Capital LLP*, 746 F.3d 1317, 1323, 110 USPQ2d 1157, 1162 (Fed. Cir. 2014) (quoting *Octocom Sys. Inc. v. Hous. Computers Servs. Inc.*, 918 F.2d 937, 942, 16 USPQ2d 1783, 1787 (Fed. Cir. 1990)).

In this case, the identifications set forth in the application and registration have no restrictions as to nature, type, channels of trade, or classes of purchasers. Therefore, it is presumed that these services “travel in the same channels of trade to the same class of purchasers.” *In re Viterro Inc.*, 671 F.3d 1358, 1362, 101 USPQ2d 1905, 1908 (Fed. Cir. 2012) (quoting *Hewlett-Packard Co. v. Packard Press, Inc.*, 281 F.3d 1261, 1268, 62 USPQ2d 1001, 1005 (Fed. Cir. 2002)). Further, the application uses broad wording to describe the services and this wording is presumed to encompass all services of the type described, including those in the registrant’s more narrow identification. *See In re Jump Designs, LLC*, 80 USPQ2d 1370, 1374 (TTAB 2006) (citing *In re Elbaum*, 211 USPQ 639, 640 (TTAB 1981)).

Next, applicant provides various pharmaceutical preparations and medicines, and registrant provides “pharmaceutical advice.” In support of showing the relatedness between these complementary goods and services, the examining attorney previously attached pages from the websites of several large pharmaceutical companies including Merck, Pfizer, Bristol-Myers Squibb and Lilly, showing that these companies provide both pharmaceuticals *and* online health information and pharmaceutical advice in the nature of prescribing information about their various drugs, medication guides, material safety data sheets, medical information resources for healthcare professionals, online medical resources for patients, etc. The examining attorney now attaches additional evidence of the same variety from the websites of Abbott Laboratories, Bayer, and Roche. *Please see pp. 7-29 attached to the previous Office action, as well as*

Exhibits A-C attached to the current final Office action.

In its response, applicant dismisses the relevance of this evidence, stating that “pharmaceutical and medical advice can be lawfully dispensed only by certified and licensed practitioners, including medical doctors and pharmacists.” Therefore, the applicant concludes, the information provided on the webpages noted above “does not constitute pharmaceutical or medical advice.”

This argument is unconvincing for several reasons. First, the trademark examining attorney has attached evidence from the USPTO’s X-Search database consisting of a representative sample of third-party marks registered for use in connection with the same or similar goods and services as those of both applicant and registrant in this case. This evidence shows that the goods and services listed therein, namely “pharmaceutical advice,” pharmaceutical consultation and pharmaceutical preparations and medicines are of a kind that may emanate from a single source under a single mark. *See In re Anderson*, 101 USPQ2d 1912, 1919 (TTAB 2012); *In re Albert Trostel & Sons Co.*, 29 USPQ2d 1783, 1785-86 (TTAB 1993); *In re Mucky Duck Mustard Co.*, 6 USPQ2d 1467, 1470 n.6 (TTAB 1988); TMEP §1207.01(d)(iii). All of these registrations are based on use in commerce in the United States, which casts doubt on applicant’s assertion that a pharmaceutical manufacturer could never offer “pharmaceutical advice.”

Secondly, applicant misconstrues the wording “pharmaceutical advice” to *only* refer to providing the services of a licensed pharmacist. This is too narrow of a reading, since “pharmaceutical advice” could refer to providing advice about any number of topics related to pharmaceuticals, such as providing advice about pharmaceutical benefit management, about the manufacture of pharmaceuticals, about pharmaceutical research and development, about general information relating to pharmaceuticals, etc. Thus, the examining attorney’s evidence showing that large pharmaceutical manufacturers also provide online health information and advice in the nature of prescribing information about their various drugs, medication guides, material safety data sheets, medical information resources for healthcare professionals, online medical resources for patients, etc., is clearly relevant.

Consumers are likely to be confused by the use of similar marks on or in connection with goods and with services featuring or related to those goods. TMEP §1207.01(a)(ii); *see In re Hyper Shoppes (Ohio), Inc.*, 837 F.2d 463, 6 USPQ2d 1025 (Fed. Cir. 1988) (holding BIGG’S for retail grocery and general merchandise store services likely to be confused with BIGGS for furniture); *In re United Serv. Distribs., Inc.*, 229 USPQ 237 (TTAB 1986) (holding design for distributorship services in the field of health and beauty aids likely to be confused with design for skin cream); *In re Phillips-Van Heusen Corp.*, 228 USPQ 949 (TTAB 1986) (holding 21 CLUB for various items of men’s, boys’, girls’ and women’s clothing likely to be confused with THE “21” CLUB (stylized) for restaurant services and towels); *In re U.S. Shoe Corp.*, 229 USPQ 707 (TTAB 1985) (holding CAREER IMAGE (stylized) for retail women’s clothing store services and clothing likely to be confused with CREST CAREER IMAGES (stylized) for uniforms); *Steelcase Inc. v. Steelcare Inc.*, 219 USPQ 433 (TTAB 1983) (holding STEELCARE INC. for refinishing of furniture, office furniture, and machinery likely to be confused with STEELCASE for office furniture and accessories); *Mack Trucks, Inc. v. Huskie Freightways, Inc.*, 177 USPQ 32 (TTAB 1972) (holding similar marks for trucking services and on motor trucks and buses likely to cause confusion).

Last, applicant argues that potential purchasers of these goods and services will “exhibit a significant degree of care,” and are therefore less likely to be confused. This argument is without merit, especially in light of the fact that the marks “CALICO” are identical. The fact that purchasers are sophisticated or knowledgeable in a particular field, such as their own healthcare, does not necessarily mean that they are sophisticated or knowledgeable in the field of trademarks or immune from source confusion. TMEP §1207.01(d)(vii); *see, e.g., Stone Lion Capital Partners, LP v. Lion Capital LLP*, 746 F.3d 1317, 1325,

110 USPQ2d 1157, 1163-64 (Fed. Cir. 2014); *Top Tobacco LP v. N. Atl. Operating Co.*, 101 USPQ2d 1163, 1170 (TTAB 2011).

For example, the mark WebMD® is widely known in the U.S. for a website which provides a wide array of medical information and advice, including advice and information about pharmaceuticals. If an unrelated company suddenly began using the identical mark “WebMD” on pharmaceutical preparations and medicines, it is likely that even the savviest of consumers would assume the drugs emanated from the original WebMD® source.

Given that the marks at issue are identical and that the evidence of record clearly supports the conclusion that the goods and services are “related in some manner” and that the circumstances surrounding their marketing “could give rise to the mistaken belief that [the goods and services] emanate from the same source,” any doubt as to whether there may be a likelihood of confusion between the respective marks must be resolved in favor of the registrant. Accordingly, the refusal to register under Section 2(d) of the Trademark Act due to a likelihood of confusion is proper, and is now maintained and made *final*.

Response Guidelines

Applicant must respond within six months of the date of issuance of this final Office action or the following goods and services to which the final refusal applies will be **deleted** from the application by Examiner’s Amendment: “pharmaceutical preparations, namely, pharmaceuticals for the prevention and treatment of cancer, age-related conditions, and neurodegenerative disorders such as Alzheimer's disease, dementia, amyotrophic lateral sclerosis, Friedreich's ataxia, Huntington's disease, Lewy body disease, Parkinson's disease, spinal muscular atrophy, cancer, atherosclerosis, arthritis, cataracts, osteoarthritis, and cardiovascular disease” and “medicines for the treatment of aging, immunological diseases and degenerative conditions of the body, the promotion of life extension and restoration of youthful bodily functions, namely, Alzheimer's disease, dementia, amyotrophic lateral sclerosis, Friedreich's ataxia, Huntington's disease, Lewy body disease, Parkinson's disease, spinal muscular atrophy, cancer, atherosclerosis, arthritis, cataracts, osteoarthritis, and cardiovascular disease” in Class 5; and “providing medical information, consultancy, and advisory services for the treatment of aging, immunological diseases and degenerative conditions of the body, the promotion of life extension, and restoration of youthful bodily functions” in Class 44. 37 C.F.R. §2.65(a); *see* 15 U.S.C. §1062(b).

The application will then proceed for all other goods and services presently listed in the application.

Applicant may respond by providing one or both of the following:

- (1) A response that fully satisfies all outstanding requirements and/or resolves all outstanding refusals.
- (2) An appeal to the Trademark Trial and Appeal Board, with the appeal fee of \$100 per class.

37 C.F.R. §2.63(b)(1)-(2); TMEP §714.04; *see* 37 C.F.R. §2.6(a)(18); TBMP ch. 1200.

In certain rare circumstances, an applicant may respond by filing a petition to the Director pursuant to 37 C.F.R. §2.63(b)(2) to review procedural issues. TMEP §714.04; *see* 37 C.F.R. §2.146(b); TBMP §1201.05; TMEP §1704 (explaining petitionable matters). The petition fee is \$100. 37 C.F.R. §2.6(a)(15).

Assistance

If applicant has any questions or needs assistance in responding to this Office Action, please telephone or email the undersigned examining attorney.

/Allison P. Schrody/
Examining Attorney
Law Office 115
allison.schrody@uspto.gov
(571) 272-5893
(571) 273-9115 (fax)

TO RESPOND TO THIS LETTER: Go to http://www.uspto.gov/trademarks/teas/response_forms.jsp. Please wait 48-72 hours from the issue/mailing date before using the Trademark Electronic Application System (TEAS), to allow for necessary system updates of the application. For *technical* assistance with online forms, e-mail TEAS@uspto.gov. For questions about the Office action itself, please contact the assigned trademark examining attorney. **E-mail communications will not be accepted as responses to Office actions; therefore, do not respond to this Office action by e-mail.**

All informal e-mail communications relevant to this application will be placed in the official application record.

WHO MUST SIGN THE RESPONSE: It must be personally signed by an individual applicant or someone with legal authority to bind an applicant (i.e., a corporate officer, a general partner, all joint applicants). If an applicant is represented by an attorney, the attorney must sign the response.

PERIODICALLY CHECK THE STATUS OF THE APPLICATION: To ensure that applicant does not miss crucial deadlines or official notices, check the status of the application every three to four months using the Trademark Status and Document Retrieval (TSDR) system at <http://tsdr.uspto.gov/>. Please keep a copy of the TSDR status screen. If the status shows no change for more than six months, contact the Trademark Assistance Center by e-mail at TrademarkAssistanceCenter@uspto.gov or call 1-800-786-9199. For more information on checking status, see <http://www.uspto.gov/trademarks/process/status/>.

TO UPDATE CORRESPONDENCE/E-MAIL ADDRESS: Use the TEAS form at <http://www.uspto.gov/trademarks/teas/correspondence.jsp>.

Print: Jan 19, 2015

76116189

DESIGN MARK

Serial Number

76116189

Status

REGISTERED AND RENEWED

Word Mark

CAPELLON

Standard Character Mark

No

Registration Number

2606705

Date Registered

2002/08/13

Type of Mark

SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(1) TYPED DRAWING

Owner

Capellon Pharmaceuticals, LLC LIMITED LIABILITY COMPANY TEXAS 7509
Flagstone Street Forth Worth TEXAS 76118

Goods/Services

Class Status -- ACTIVE. IC 042. US 100 101. G & S: Pharmaceutical
advice. First Use: 1999/01/03. First Use In Commerce: 1999/01/03.

Goods/Services

Class Status -- ACTIVE. IC 040. US 100 103 106. G & S: Custom
manufacture of pharmaceutical preparations. First Use: 1999/01/03.
First Use In Commerce: 1999/01/03.

Filing Date

2000/08/25

Examining Attorney

FRENCH, CURTIS

Attorney of Record

Stephen M. Roylance

CAPELLON

Print: Jan 19, 2015

76523912

DESIGN MARK

Serial Number

76523912

Status

REGISTERED AND RENEWED

Word Mark

C.O. BIGELOW ESTABLISHED 1836 APOTHECARIES

Standard Character Mark

No

Registration Number

2802209

Date Registered

2004/01/06

Type of Mark

TRADEMARK; SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(3) DESIGN PLUS WORDS, LETTERS AND/OR NUMBERS

Owner

BIGELOW MERCHANDISING, LLC LIMITED LIABILITY COMPANY DELAWARE THREE LIMITED PARKWAY COLUMBUS OHIO 43230

Goods/Services

Class Status -- ACTIVE. IC 003. US 001 004 006 050 051 052. G & S: Skin care products, namely, cleansing creams, scrubs, soaps, masques, toners, conditioners and moisturizers; sunscreen and suntan oils and creams; shaving creams, after shave creams and lotions, body massage creams and oils, bath oils, body wash and shower gels, talcum powders, body scrubs; hair care products, namely, shampoos, conditioners and grooming preparations; fragrances, namely, perfumes, colognes, and essences; essential oils and aromatherapy oils; cosmetics, namely, nail polish, lipstick, lip balms, eyeshadow, blush, facial powder, mascara and eyeliners, medicated soaps. First Use: 1970/01/01. First Use In Commerce: 1970/01/01.

Goods/Services

Class Status -- ACTIVE. IC 005. US 006 018 044 046 051 052. G & S: Vitamins, over-the-counter medicines, namely, preparations for treating colds, throat lozenges, cough lozenges, medicated lozenges, cough syrups, and aspirin, medicated lip balm, medicated skin

Print: Jan 19, 2015

76523912

preparations and lotions, medicated sunburn lotions, air deodorant and air deodorizers. First Use: 1970/01/01. First Use In Commerce: 1970/01/01.

Goods/Services

Class Status -- ACTIVE. IC 018. US 001 002 003 022 041. G & S: Toiletry and cosmetic cases and toiletry and cosmetic bags sold empty. First Use: 1997/01/01. First Use In Commerce: 1997/01/01.

Goods/Services

Class Status -- ACTIVE. IC 021. US 002 013 023 029 030 033 040 050. G & S: Make-up brushes and shaving brushes; combs and hair brushes. First Use: 1991/01/01. First Use In Commerce: 1991/01/01.

Goods/Services

Class Status -- ACTIVE. IC 035. US 100 101 102. G & S: Mail order services, on-line retail store services and retail shops, all featuring pharmaceutical products, cosmetics, toiletries, spa, skin and beauty care products; retail pharmacy and cosmetic product services; wholesale and retail store and distributorship services featuring pharmaceutical products, cosmetics, toiletries, spa, skin and beauty care products. First Use: 1900/01/01. First Use In Commerce: 1900/01/01.

Goods/Services

Class Status -- ACTIVE. IC 044. US 100 101. G & S: Pharmaceutical advice, health spa services, namely cosmetic and body care services. First Use: 1900/01/01. First Use In Commerce: 1900/01/01.

Goods/Services

Class Status -- ACTIVE. IC 045. US 100 101. G & S: Preparation of gift baskets with selected cosmetic and body care items. First Use: 1900/01/01. First Use In Commerce: 1900/01/01.

Prior Registration(s)

2365803;2460091

Disclaimer Statement

NO CLAIM IS MADE TO THE EXCLUSIVE RIGHT TO USE "ESTABLISHED 1836 APOTHECARIES" APART FROM THE MARK AS SHOWN.

Name/Portrait Statement

The name "C.O. BIGELOW" does not identify a living individual.

Colors Claimed

Color is not claimed as a feature of the mark.

Section 2f Statement

as to "C.O. BIGELOW"

Filing Date

Print: Jan 19, 2015

76523912

2003/06/09

Examining Attorney

CASE, LEIGH CAROLINE

Attorney of Record

Joseph Quigley



Print: Jan 19, 2015

76680992

DESIGN MARK

Serial Number

76680992

Status

REGISTERED

Word Mark

NEUROPATTERN

Standard Character Mark

Yes

Registration Number

3944388

Date Registered

2011/04/12

Type of Mark

TRADEMARK; SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(4) STANDARD CHARACTER MARK

Owner

Hellhammer, Juliane INDIVIDUAL FED REP GERMANY Max-Planck-Str. 22
D-54295 Trier FED REP GERMANY

Goods/Services

Class Status -- ACTIVE. IC 005. US 006 018 044 046 051 052. G & S: pharmaceutical and veterinary preparations for the prevention and treatment of stress related disorders in humans and animals. First Use: 2011/01/19. First Use In Commerce: 2011/01/19.

Goods/Services

Class Status -- ACTIVE. IC 042. US 100 101. G & S: Scientific and technological research services and design of new products relating thereto for others; scientific and industrial research services and analysis related thereto for medical purposes, namely, the development and analysis of medicaments for various conditions of persons and animals, particularly for stress related syndromes and other diseases of the human and animal body, and the determination of their spectrum of efficacy. First Use: 2010/02/03. First Use In Commerce: 2010/02/03.

Goods/Services

Print: Jan 19, 2015

76680992

Class Status -- ACTIVE. IC 044. US 100 101. G & S: Medical services, namely, medical analysis services relating to the treatment of persons and animals, such as the analysis of stress related syndromes and other diseases of the human and animal body; pharmaceutical advice. First Use: 2011/01/00. First Use In Commerce: 2011/01/00.

Colors Claimed

Color is not claimed as a feature of the mark.

Filing Date

2005/09/26

Examining Attorney

MEIER, SHARON

Attorney of Record

Lynn A. Sullivan

NEUROPATTERN

Print: Jan 19, 2015

77004855

DESIGN MARK

Serial Number

77004855

Status

REGISTERED

Word Mark

DAEWOONG PHARMACEUTICAL CO., LTD.

Standard Character Mark

No

Registration Number

3966537

Date Registered

2011/05/24

Type of Mark

TRADEMARK; SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(3) DESIGN PLUS WORDS, LETTERS AND/OR NUMBERS

Owner

Daewoong Co., Ltd. CORPORATION REPUBLIC OF KOREA 223-23,
Sangdaewon-Dong, Joongwon-Ku Sunnam-city Kyunggido REPUBLIC OF KOREA
462-120

Goods/Services

Class Status -- ACTIVE. IC 005. US 006 018 044 046 051 052. G & S:
Pharmaceutical preparations, namely, acetaminophen, acne medications,
acne treatment preparations, adrenal hormone preparations, alcohol for
topical use, allergy and allergy relief medications, analgesics,
androgen preparations, anesthetics for surgical and non surgical use,
antacids, bactericides, antiarrhythmics, antibiotics, anticoagulants,
anticonvulsants, antidepressants, antidiabetic preparations,
antivirals, anti-cancer preparations, anti-infectives,
anti-inflammatories, antipyretics, antibacterial pharmaceuticals,
calcium channel blockers, beta blockers, chemical compounds for drug
delivery, eye drops, eye patches for medical purposes, hair growth
stimulants, vaccines, vaccine adjuvants, vaccine stabilizers,
diuretics, amino acids for medical purposes; dietary and nutritional
supplements; medicated skin lotions, bandages for skin wounds,
vitamins; biological preparations for medical purposes; all purpose
disinfecting and deodorizing preparations; pharmaceutical preparations

Print: Jan 19, 2015**77004855**

for use in cardiovascular treatment; diagnostic agents for medical purposes; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for treating wounds; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations to prevent swelling in the legs; pharmaceutical preparations for treating respiratory diseases and asthma; pharmaceutical preparations for the treatment of erectile dysfunction; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; processed food adapted for medical purposes; plant extracts adapted for use in the treatment of the central nervous system, diabetes, skin disorders, wounds, eye diseases and conditions, swelling in the legs, respiratory diseases, asthma, erectile dysfunction, cardiovascular conditions, heart rhythm disorders and infectious diseases; plant extracts adapted for use in chemotherapy; veterinary preparations for treatment of intestinal bacteria in mammals; veterinary preparations, namely, vaccines; sanitary preparations for medical use. First Use: 2002/05/14. First Use In Commerce: 2010/10/01.

Goods/Services

Class Status -- ACTIVE. IC 035. US 100 101 102. G & S: Pharmaceutical sales promotion for others; providing business information for pharmaceuticals; business management assistance on pharmaceuticals; market research; market study; advertising services; arranging of pharmaceutical sale, namely, procuring of contracts for the purchase and sale of pharmaceuticals, retail services by direct solicitation by sales agents in the field of pharmaceuticals; export-import agency; retail store services in the field of health supplements, retail services by direct solicitation by sales agents in the field of health supplements; retail store services in the field of cosmetics, retail services by direct solicitation by sales agents in the field of cosmetics; and procurement services, namely, purchasing pharmaceuticals for others. First Use: 2002/05/14. First Use In Commerce: 2009/11/01.

Goods/Services

Class Status -- ACTIVE. IC 044. US 100 101. G & S: Medical clinics; pharmaceutical advice; preparation and dispensing of pharmaceuticals; technology services on selecting medicines, namely, interactive medical monitoring and alert services for reminding clients of medical information, namely, medicinal dosage, allergic sensitivity and prescription refills; providing medical information about medical equipment, devices and pharmaceutical preparations; clinical pathology services for the diagnosis and treatment of disease; medical assistance services; medical testing service; medical and health care, namely, ambulant medical care; cosmetic analysis;

Print: Jan 19, 2015

77004855

rental of medical equipment; rental of sanitary equipment, namely, clean chambers for sanitary purposes, urinals for sanitary fixtures, hand washing basins and bowls for sanitary installations and water pipes for sanitary installations. First Use: 2002/05/14. First Use In Commerce: 2009/11/01.

Disclaimer Statement

NO CLAIM IS MADE TO THE EXCLUSIVE RIGHT TO USE "PHARMACEUTICAL CO., LTD." APART FROM THE MARK AS SHOWN.

Description of Mark

The mark consists of the term "DAEWOONG" above the words "PHARMACEUTICAL CO., LTD.". To the left of the words is a shaded square containing a Chinese character on the left and a picture of a bear on the right.

Colors Claimed

Color is not claimed as a feature of the mark.

Translation Statement

The English translation of the word "DAEWOONG" in the mark is Big Bear.

Transliteration Statement

The non-Latin character(s) in the mark transliterates into "woong" , and this means a bear in English.

Filing Date

2006/09/21

Examining Attorney

MITTLER, ROBIN

Attorney of Record

Kelly Phair McCarthy



Print: Jan 19, 2015

77098427

DESIGN MARK

Serial Number

77098427

Status

REGISTERED

Word Mark

THE COMPOUNDING SHOP PROVIDING YOU HEALTH & WELLNESS THROUGH
CUSTOMIZED MEDICATIONS

Standard Character Mark

No

Registration Number

3358605

Date Registered

2007/12/25

Type of Mark

TRADEMARK; SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(3) DESIGN PLUS WORDS, LETTERS AND/OR NUMBERS

Owner

The Compounding Shop, Inc. CORPORATION FLORIDA 4000 Park Street North
St. Petersburg FLORIDA 33709

Goods/Services

Class Status -- ACTIVE. IC 005. US 006 018 044 046 051 052. G & S:
Acne medications; Allergy medications; Almond oils for pharmaceutical
purposes; Amino acids for medical or veterinary purposes; Animal feed
additive for use as a nutritional supplement for medical purposes;
Antibacterial pharmaceuticals; Antifungal creams for medical use;
Antimicrobial preparations for inhibiting microbiological
decomposition in food, beverages, animal feed and pharmaceuticals;
Astringents; Bacteriostats for medicinal, dental and veterinary use;
Bath salts for medical purposes; Biological and chemical preparations
and reagents for medical or veterinary use; Bismuth preparations for
pharmaceutical purposes; Burn relief medication; Cardiovascular
pharmaceuticals; Castor oil; Cleansing solutions for medical use;
Dermatological pharmaceutical products; Diagnostic agents,
preparations and substances for medical purposes; Diarrhea medication;
Drug delivery agents consisting of compounds that facilitate delivery
of a wide range of pharmaceuticals; Electrophoresis gels for medical

Print: Jan 19, 2015**77098427**

or veterinary purposes; Fungicides for medical use; Gelatin capsules sold empty for pharmaceuticals; Ginseng for medicinal use; Hormones for medical purposes; Hydrogen peroxide for medical use; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Injectable pharmaceuticals for treatment of anaphylactic reactions; Isopropyl alcohol for medical use; Medical cleansers for skin and wounds; Medical lubricant, namely, vaginal lubricants; Medicated animal feed; Medicated baby oils; Medicated baby powders; Medicated bath preparations; Medicated brush-on oral care gels; Medicated candies; Medicated diaper rash ointments and lotions; Medicated foot powder; Medicated grooming preparations for pets and livestock, namely, shampoos, lotions, creams, and sprays to treat and prevent a variety of conditions; Medicated hair care preparations; Medicated hand wash; Medicated lip balm; Medicated lozenges; Medicated mouth care and treatment preparations; Medicated shaving preparations; Medicinal herbal extracts for medical purposes; Mineral salts for medical purposes; Multipurpose medicated antibiotic cream, analgesic balm and mentholated salve.; Pain relief medication; Parasitocides for medical use; Petroleum jelly for medical purposes; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations namely, antidepressants; Pharmaceutical preparations namely, appetite suppressants; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Syringes sold filled with hormone replacement, arthritic medication, allergy medication. First Use: 2007/02/02. First Use In Commerce: 2007/02/02.

Goods/Services

Class Status -- ACTIVE. IC 035. US 100 101 102. G & S: Retail pharmacy services. First Use: 2007/02/02. First Use In Commerce: 2007/02/02.

Goods/Services

Class Status -- ACTIVE. IC 042. US 100 101. G & S: Development of pharmaceutical preparations and medicines; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research and development; Pharmaceutical research

Print: Jan 19, 2015

77098427

services; Research and development of vaccines and medicines; Research on the subject of pharmaceuticals. First Use: 2007/02/02. First Use In Commerce: 2007/02/02.

Goods/Services

Class Status -- ACTIVE. IC 044. US 100 101. G & S: Dispensing of pharmaceuticals; Medical and pharmaceutical consultation; Pharmaceutical advice; Pharmacists' services to make up prescriptions; Preparation and dispensing of medications. First Use: 2007/02/02. First Use In Commerce: 2007/02/02.

Disclaimer Statement

NO CLAIM IS MADE TO THE EXCLUSIVE RIGHT TO USE "THE COMPOUNDING SHOP" APART FROM THE MARK AS SHOWN.

Description of Mark

The mark consists of a stylized teal word "The" superimposed above a stylized maroon word "Compounding" superimposed above a stylized maroon word "Shop" with a stylized teal symbol of a mortar with pestle immediately to the right of the word "Shop" that is partially superimposed above the "p" in the word "Shop" with the stylized white symbol "Rx" superimposed inside the symbol of the mortar, all of which appears superimposed above the stylized black italicized words "Providing You Health & Wellness Through Customized Medications".

Colors Claimed

The color(s) teal, maroon, white, and black is/are claimed as a feature of the mark.

Filing Date

2007/02/02

Examining Attorney

LITZAU, MICHAEL

Attorney of Record

Carla Turner-Hahn

The Compounding Shop

*Providing You Health & Wellness
Through Customized Medications*

Print: Jan 19, 2015

78717824

DESIGN MARK

Serial Number

78717824

Status

REGISTERED

Word Mark

ALBIOREX

Standard Character Mark

Yes

Registration Number

3613899

Date Registered

2009/04/28

Type of Mark

TRADEMARK; SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(4) STANDARD CHARACTER MARK

Owner

ALBIOREX, INC. CORPORATION FLORIDA P.O. Box 773 Palm Harbor FLORIDA
346820773

Goods/Services

Class Status -- ACTIVE. IC 005. US 006 018 044 046 051 052. G & S:
Pharmaceuticals, namely, human collagen; pharmaceutical preparations
for dermatologic use, ocular or intraocular surgery and
ophthalmological use, orthopedic surgery and orthopedic use. First
Use: 2008/03/18. First Use In Commerce: 2008/03/18.

Goods/Services

Class Status -- ACTIVE. IC 035. US 100 101 102. G & S:
Distributorships in the field of pharmaceutical and medical products;
retail pharmacy services; wholesale ordering services in the field of
pharmaceutical and medical products. First Use: 2008/03/18. First
Use In Commerce: 2008/03/18.

Goods/Services

Class Status -- ACTIVE. IC 042. US 100 101. G & S: Scientific and
technological services and research and design relating thereto,
namely, biotechnology research, design, engineering and manufacture of

Print: Jan 19, 2015

78717824

collagen, cells, and tissue related materials, drug delivery systems, and orthopedic and ophthalmological materials. First Use: 2008/03/18. First Use In Commerce: 2008/03/18.

Goods/Services

Class Status -- ACTIVE. IC 044. US 100 101. G & S: Medical services; medical care, hygienic and beauty care given by persons or establishments to human beings and animals, namely, beauty salon services, veterinary services; plastic and cosmetic surgery; ophthalmological surgery and services, orthopedic surgery, medical and pharmaceutical advice and consultation. First Use: 2008/03/18. First Use In Commerce: 2008/03/18.

Filing Date

2005/09/21

Examining Attorney

GUSTASON, ANNE E.

Attorney of Record

Mark D. Hansing

ALBIOREX

Print: Jan 20, 2015

76604825

DESIGN MARK

Serial Number

76604825

Status

SECTION 8 & 15-ACCEPTED AND ACKNOWLEDGED

Word Mark

COMPOUND WITH CONFIDENCE

Standard Character Mark

Yes

Registration Number

3052455

Date Registered

2006/01/31

Type of Mark

TRADEMARK; SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(4) STANDARD CHARACTER MARK

Owner

Professional Compounding Centers of America, Inc. CORPORATION TEXAS
9901 South Wilcrest Drive Houston TEXAS 77099

Goods/Services

Class Status -- ACTIVE. IC 001. US 001 005 006 010 026 046. G & S:
Chemicals for use in compounding pharmaceuticals. First Use:
2004/02/00. First Use In Commerce: 2004/02/00.

Goods/Services

Class Status -- ACTIVE. IC 003. US 001 004 006 050 051 052. G & S:
Non-medicated formulations, namely, base skin creams, lotions, liquids
and semi-solids for use with other cosmetics. First Use: 2004/02/00.
First Use In Commerce: 2004/02/00.

Goods/Services

Class Status -- ACTIVE. IC 005. US 006 018 044 046 051 052. G & S:
Base formulations, mainly, creams, lotions, liquids and semi-solids
for use with medicated ingredients for formulating topical
pharmaceutical preparations. First Use: 2004/02/00. First Use In
Commerce: 2004/02/00.

Print: Jan 20, 2015

76604825

Goods/Services

Class Status -- ACTIVE. IC 007. US 013 019 021 023 031 034 035. G & S: Equipment used in formulating pharmaceutical products, namely, capsule making machines, ointment mills, rapid dissolve equipment in the form of high speed mixers, and machine parts, namely, molds for use in the manufacture pharmaceutical formulations, namely, suppositories, suckers and tablets. First Use: 2004/02/00. First Use In Commerce: 2004/02/00.

Goods/Services

Class Status -- ACTIVE. IC 035. US 100 101 102. G & S: Business consultation services in the field of marketing pharmaceutical compounding services. First Use: 2004/02/00. First Use In Commerce: 2004/02/00.

Goods/Services

Class Status -- ACTIVE. IC 041. US 100 101 107. G & S: Educational services, namely, conducting classes, conferences and workshops in the fields of compounding pharmaceuticals, marketing pharmaceutical compounding services and financial management for compounding pharmacies. First Use: 2004/02/00. First Use In Commerce: 2004/02/00.

Goods/Services

Class Status -- ACTIVE. IC 044. US 100 101. G & S: Pharmaceutical consultation services to pharmacists in the field of compounding and providing information related thereto via global computer network. First Use: 2004/02/00. First Use In Commerce: 2004/02/00.

Prior Registration(s)

1252120;1319791;1325398;2655708;2661704;2714999;AND OTHERS

Filing Date

2004/07/30

Examining Attorney

CLARK, GLENN

Attorney of Record

C. James Bushman

COMPOUND WITH CONFIDENCE

Print: Jan 20, 2015

77029507

DESIGN MARK

Serial Number

77029507

Status

SECTION 8 & 15-ACCEPTED AND ACKNOWLEDGED

Word Mark

HORTON & CONVERSE

Standard Character Mark

Yes

Registration Number

3387426

Date Registered

2008/02/26

Type of Mark

TRADEMARK; SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(4) STANDARD CHARACTER MARK

Owner

Gavin Herbert Co. DBA Horton & Converse Pharmacies CORPORATION
CALIFORNIA 23 Corporate Plaza, Suite 123 Newport Beach CALIFORNIA
92660

Goods/Services

Class Status -- ACTIVE. IC 005. US 006 018 044 046 051 052. G & S:
Vitamin and mineral preparations for medical use. First Use:
1917/00/00. First Use In Commerce: 1917/00/00.

Goods/Services

Class Status -- ACTIVE. IC 035. US 100 101 102. G & S: Retail
pharmacy services. First Use: 1917/00/00. First Use In Commerce:
1917/00/00.

Goods/Services

Class Status -- ACTIVE. IC 044. US 100 101. G & S: Maintaining
personal medical history records and files; Medical and pharmaceutical
consultation; Preparation and dispensing of medications; Rental of
medical equipment. First Use: 1917/00/00. First Use In Commerce:
1917/00/00.

Print: Jan 20, 2015

77029507

Filing Date
2006/10/25

Examining Attorney
PERKINS, ELLEN

Horton & Converse

Print: Jan 20, 2015

77614807

DESIGN MARK

Serial Number

77614807

Status

REGISTERED

Word Mark

MOCHI MED SPA

Standard Character Mark

Yes

Registration Number

3783309

Date Registered

2010/05/04

Type of Mark

TRADEMARK; SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(4) STANDARD CHARACTER MARK

Owner

Hansen A. Chang, L.L.C. LIMITED LIABILITY COMPANY GEORGIA 2253 Grain Meadow Lane Stone Mountain GEORGIA 300892764

Goods/Services

Class Status -- ACTIVE. IC 005. US 006 018 044 046 051 052. G & S: Dermatological pharmaceutical products; Medicated skin care preparations. First Use: 2009/08/01. First Use In Commerce: 2009/08/01.

Goods/Services

Class Status -- ACTIVE. IC 044. US 100 101. G & S: Medical and pharmaceutical consultation; Medical services. First Use: 2009/06/01. First Use In Commerce: 2009/08/01.

Disclaimer Statement

NO CLAIM IS MADE TO THE EXCLUSIVE RIGHT TO USE "MED SPA" APART FROM THE MARK AS SHOWN.

Filing Date

2008/11/14

Print: Jan 20, 2015

77614807

Examining Attorney
RINGLE, JIM

MOCHI MED SPA

Print: Jan 20, 2015

77710229

DESIGN MARK

Serial Number

77710229

Status

REGISTERED

Word Mark

HNP PHARMACEUTICALS

Standard Character Mark

No

Registration Number

3701435

Date Registered

2009/10/27

Type of Mark

TRADEMARK; SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(3) DESIGN PLUS WORDS, LETTERS AND/OR NUMBERS

Owner

Robert P. Nickell INDIVIDUAL UNITED STATES 381 Van Ness Avenue, Suite 1507 Torrance CALIFORNIA 90501

Goods/Services

Class Status -- ACTIVE. IC 005. US 006 018 044 046 051 052. G & S: pain relief medication; topical gel for medical and therapeutic treatment of inflammation and pain; medicinal creams for skin care; topical analgesics; oral analgesics. First Use: 1995/06/01. First Use In Commerce: 1995/06/01.

Goods/Services

Class Status -- ACTIVE. IC 044. US 100 101. G & S: pharmaceutical consultation in the field of prescribing medications and compounding of prescription medications; pharmacists' services to make up prescriptions. First Use: 1995/06/01. First Use In Commerce: 1995/06/01.

Disclaimer Statement

NO CLAIM IS MADE TO THE EXCLUSIVE RIGHT TO USE "PHARMACEUTICALS" APART FROM THE MARK AS SHOWN.

Print: Jan 20, 2015

77710229

Description of Mark

The mark consists of the term "HNP PHARMACEUTICALS" with the term "HNP" appearing in white on a blue rectangular background, followed by the term "PHARMACEUTICALS" in black on a white rectangular background, all surrounded by a black border.

Colors Claimed

The color(s) blue, white and black is/are claimed as a feature of the mark.

Filing Date

2009/04/09

Examining Attorney

STOIDES, KATHERINE

Attorney of Record

Irene Y. Lee



Print: Jan 20, 2015

78401390

DESIGN MARK

Serial Number

78401390

Status

REGISTERED

Word Mark

TIBOTEC

Standard Character Mark

Yes

Registration Number

3573904

Date Registered

2009/02/10

Type of Mark

TRADEMARK; SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(4) STANDARD CHARACTER MARK

Owner

JANSSEN R&D IRELAND CORPORATION IRELAND EASTGATE VILLAGE, EASTGATE
LITTLE ISLAND CO. CORK IRELAND

Goods/Services

Class Status -- ACTIVE. IC 005. US 006 018 044 046 051 052. G & S:
Pharmaceutical preparations for treatment of Alzheimer's disease;
bacterial disease, fungal disease, protozoal disease, viral
conditions, cancer, neoplastic conditions, tumors; analgesics,
antipyretics; pharmaceutical preparations for treating diseases and
disorders of the nervous system, metabolic diseases and disorders,
diseases and disorders of the cardiovascular system, diseases and
disorders of the endocrine system, diseases and disorders of the
immune system, diseases and disorders of the respiratory system,
diseases and disorders of the gastrointestinal tract. First Use:
2006/06/26. First Use In Commerce: 2006/06/26.

Goods/Services

Class Status -- ACTIVE. IC 042. US 100 101. G & S: Scientific
research; laboratory research in the field of bacteriology, virology,
antifungals, oncology, biotechnology, biochemistry and alzheimers;
testing, inspection or research of pharmaceuticals; research on the

Print: Jan 20, 2015

78401390

subject of pharmaceuticals; consultation in the field of pharmaceutical screening and testing; chemical analysis; research and development of new products for others; chemical consultation in the field of combinatorial chemistry. First Use: 2006/06/26. First Use In Commerce: 2006/06/26.

Filing Date

2004/04/14

Examining Attorney

SOUDERS, MICHAEL

Attorney of Record

Robert J. Kenney

TIBOTEC

Print: Jan 20, 2015

85562204

DESIGN MARK

Serial Number

85562204

Status

REGISTERED

Word Mark

SINUS DYNAMICS

Standard Character Mark

Yes

Registration Number

4445926

Date Registered

2013/12/10

Type of Mark

TRADEMARK; SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(4) STANDARD CHARACTER MARK

Owner

SinuTopic, Inc. CORPORATION DELAWARE 755 Lakefield Road, Units C, D & E Westlake Village CALIFORNIA 91361

Goods/Services

Class Status -- ACTIVE. IC 005. US 006 018 044 046 051 052. G & S: Antibacterial pharmaceuticals; antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals; dermatological pharmaceutical products; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; homeopathic pharmaceuticals for use in the treatment of sinusitis; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; inhalers filled with anti-infectives; pharmaceutical anti-allergic preparations and substances; pharmaceutical antitussive-cold preparations ; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of sinusitis; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in chemotherapy;

Print: Jan 20, 2015**85562204**

pharmaceutical preparations for use in dermatology; pharmaceutical products for ophthalmological use; pharmaceutical products for the treatment of viral and infectious diseases and cancer; pharmaceutical products for treating respiratory diseases and asthma; pharmaceuticals, namely, anti-infectives; synthetic peptides for the treatment of sinus conditions and diseases; vitamin and mineral preparations for use as ingredients in the food and pharmaceutical industry. First Use: 2006/05/00. First Use In Commerce: 2006/05/00.

Goods/Services

Class Status -- ACTIVE. IC 035. US 100 101 102. G & S: Retail pharmacy services; retail store pharmacy services in the field of prescription drugs; mail order pharmacy services; mail order services featuring pharmaceuticals; specialty pharmaceutical distributorship services; pharmaceutical cost management for the health care benefit plans of others; retail and online retail store pharmacy services in the field of prescription drugs, healthcare and beauty products; retail store and mail order pharmacy services in the field of prescription drugs and the distribution of drug therapy information in connection therewith; retail store services, namely, pharmacy, drug and general merchandise store services; mail order of pharmaceuticals, specialty pharmaceutical distributorship services; pharmaceutical cost management for health care benefit plans for others; administering pharmacy reimbursement programs and services; promoting public awareness of the value of using generic drugs; processing mail order prescription drug refill orders in retail and central fill pharmacies; processing online and telephone prescription orders in retail and central fill pharmacies. First Use: 2006/05/00. First Use In Commerce: 2006/05/00.

Goods/Services

Class Status -- ACTIVE. IC 044. US 100 101. G & S: Pharmaceutical consultation; consulting with patients regarding the administration of medicine and the use of medical devices; providing a physician resource for clinical questions about medications; providing a website featuring information about, and through which, customers can obtain information about general health topics, pharmaceutical therapies and disease state management; providing medical information regarding patients, prescription drugs and drug therapy; providing health care information and consulting services in the field of disease management and medical condition management; providing medical information regarding patients, prescription drugs and drug therapy; developing and managing comprehensive programs involving drug therapy and physician support services in the nature of providing consultation in the dispensing of pharmaceuticals for persons with chronic health issues; therapeutic pharmaceutical services, namely, the development and management of comprehensive programs comprising drug therapy and physician support services in the nature of providing consultation in the dispensing of pharmaceuticals for persons with chronic health issues; drug utilization review dispensing services, namely, identifying possible drug to drug interactions prior to dispensing new

Print: Jan 20, 2015

85562204

prescribed medications and possible drug allergic reactions given a patient's drug allergy history. First Use: 2006/05/00, First Use In Commerce: 2006/05/00.

Prior Registration(s)

3464907

Disclaimer Statement

NO CLAIM IS MADE TO THE EXCLUSIVE RIGHT TO USE "SINUS" APART FROM THE MARK AS SHOWN.

Colors Claimed

Color is not claimed as a feature of the mark.

Filing Date

2012/03/06

Examining Attorney

MICHELI, ANGELA M.

Attorney of Record

Christine M. Baker

SINUS DYNAMICS

Print: Jan 20, 2015

85619481

DESIGN MARK

Serial Number

85619481

Status

REGISTERED

Word Mark

SOLCO HEALTHCARE U.S.

Standard Character Mark

Yes

Registration Number

4478651

Date Registered

2014/02/04

Type of Mark

TRADEMARK; SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(4) STANDARD CHARACTER MARK

Owner

Solco Healthcare US, LLC LIMITED LIABILITY COMPANY DELAWARE Suite A,
2002 Eastpark Blvd. Cranbury NEW JERSEY 08512

Goods/Services

Class Status -- ACTIVE. IC 005. US 006 018 044 046 051 052. G & S:
Analgesic and muscle relaxant pharmaceutical preparations;
antibacterial pharmaceuticals; antimicrobial preservatives for
cosmetics and pharmaceuticals; pharmaceutical astringents; balms for
pharmaceutical purposes; cream of tartar for pharmaceutical purposes;
creosote for pharmaceutical purposes; dermatological pharmaceutical
products; digestives for pharmaceutical purposes; drug delivery agents
consisting of compounds that facilitate delivery of a wide range of
pharmaceuticals; drug delivery agents in the form of tablets that
provide controlled release of the active ingredients for a wide
variety of pharmaceuticals; drug delivery agents in the form of
capsules that provide controlled release of the active ingredients for
a wide variety of pharmaceuticals; drug delivery agents in the form of
powders that provide controlled release of the active ingredients for
a wide variety of pharmaceuticals; ferments for pharmaceutical
purposes; inhaled pharmaceutical preparations for the treatment of
respiratory disease; injectable pharmaceuticals for treatment of

Print: Jan 20, 2015**85619481**

anaphylactic reactions; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; iodine for pharmaceutical purposes; liquorice for pharmaceutical purposes; menthol for pharmaceutical purposes; pharmaceutical antitussive-cold preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations, namely, anticoagulants; pharmaceutical preparations, namely, appetite suppressants; pharmaceutical preparation for the treatment of gout; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for use in urology; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations, namely, injectable contraceptives; pharmaceutical preparations for treating allergies; pharmaceutical preparations for treating hypertension; pharmaceutical products for treating respiratory disease and asthma; pharmaceutical products for the treatment of joint disease; plant extracts for medical, veterinary and pharmaceutical purposes; potassium preparations for pharmaceutical purposes; pharmaceutical preparations and substances for weight loss; vitamin and mineral supplements for use as ingredients in the food and pharmaceutical industry; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of coatings for facilitating the delivery of a wide range of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; biological preparations for the treatment of cancer and autoimmune deficiencies and disorders; pharmaceutical, veterinary and sanitary preparations, namely, conjugates of organic and inorganic chemicals with polypeptides, proteins, artificial polypeptides, artificial proteins produced by genetic engineering and for the treatment of viral and infectious diseases, immune system disorders, cancer, diabetes, cardiovascular diseases, central nervous system disorders and diseases; anti-diabetic pharmaceuticals; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; cardiovascular pharmaceuticals;

Print: Jan 20, 2015

85619481

pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; pharmaceutical preparations for treating skin disorders; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer. First Use: 2009/06/03. First Use In Commerce: 2009/06/03.

Goods/Services

Class Status -- ACTIVE. IC 035. US 100 101 102. G & S: Providing business intelligence services in the fields of medical devices, pharmaceuticals and the life sciences; regulatory submission management, namely, assisting others in preparing and filing applications for new drugs with governmental regulatory bodies. First Use: 2010/12/31. First Use In Commerce: 2010/12/31.

Goods/Services

Class Status -- ACTIVE. IC 044. US 100 101. G & S: Medical and pharmaceutical consultation. First Use: 2010/12/31. First Use In Commerce: 2010/12/31.

Disclaimer Statement

NO CLAIM IS MADE TO THE EXCLUSIVE RIGHT TO USE "HEALTHCARE U.S." APART FROM THE MARK AS SHOWN.

Colors Claimed

Color is not claimed as a feature of the mark.

Filing Date

2012/05/08

Examining Attorney

RIRIE, VERNA BETH

Attorney of Record

Maureen C. Kassner

SOLCO HEALTHCARE U.S.

Print: Jan 20, 2015

85744571

DESIGN MARK

Serial Number

85744571

Status

REGISTERED

Word Mark

BIOTE

Standard Character Mark

Yes

Registration Number

4570632

Date Registered

2014/07/22

Type of Mark

TRADEMARK; SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(4) STANDARD CHARACTER MARK

Owner

bioTEmedical, Inc. CORPORATION NEVADA 800 West Arbrook Suite 100
Arlington TEXAS 76015

Goods/Services

Class Status -- ACTIVE. IC 005. US 006 018 044 046 051 052. G & S: Hormone replacement therapy preparations; Hormones; Hormones for medical purposes; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis. First Use: 2012/09/30. First Use In Commerce: 2012/09/30.

Goods/Services

Class Status -- ACTIVE. IC 041. US 100 101 107. G & S: Medical training and teaching. First Use: 2012/09/30. First Use In Commerce: 2012/09/30.

Print: Jan 20, 2015

85744571

Goods/Services

Class Status -- ACTIVE. IC 044. US 100 101. G & S: Consulting services in the field of hormone replacement therapy; Medical and pharmaceutical consultation; Medical clinic providing weight loss solutions, services and programs, nutrition counseling, hormone therapy, including, bioidentical hormone replacement, anti aging therapy, and natural hormone therapy, medical aesthetic procedures, including, laser hair removal, laser peels, botulinum toxin treatments, microdermabrasion, liposuction, vein treatments, vein therapy, cellulite treatments, body contouring treatments, injectable filler treatments, facials, and skin care. First Use: 2012/09/30. First Use In Commerce: 2012/09/30.

Filing Date

2012/10/03

Examining Attorney

DINALLO, KEVIN

Attorney of Record

Michael D. Sydow

bioTE

Print: Jan 20, 2015

85744706

DESIGN MARK

Serial Number

85744706

Status

REGISTERED

Word Mark

AGE HEALTHIER....LIVE HAPPIER!

Standard Character Mark

Yes

Registration Number

4574258

Date Registered

2014/07/29

Type of Mark

TRADEMARK; SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(4) STANDARD CHARACTER MARK

Owner

bioTEmedical, Inc. CORPORATION NEVADA 800 W. Arbrook, Suite 100
Arlington TEXAS 76015

Goods/Services

Class Status -- ACTIVE. IC 005. US 006 018 044 046 051 052. G & S: Hormone replacement therapy preparations; Hormones; Hormones for medical purposes; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis. First Use: 2012/09/30. First Use In Commerce: 2012/09/30.

Goods/Services

Class Status -- ACTIVE. IC 041. US 100 101 107. G & S: Medical training and teaching. First Use: 2012/09/30. First Use In Commerce: 2012/09/30.

Print: Jan 20, 2015

85744706

Goods/Services

Class Status -- ACTIVE. IC 044. US 100 101. G & S: Consulting services in the field of hormone replacement therapy; Medical and pharmaceutical consultation; Medical clinic providing weight loss solutions, services and programs, nutrition counseling, hormone therapy, including, bioidentical hormone replacement, anti aging therapy, and natural hormone therapy, medical aesthetic procedures, including, laser hair removal, laser peels, botulinum toxin treatments, microdermabrasion, liposuction, vein treatments, vein therapy, cellulite treatments, body contouring treatments, injectable filler treatments, facials, and skin care. First Use: 2012/09/30. First Use In Commerce: 2012/09/30.

Filing Date

2012/10/03

Examining Attorney

DINALLO, KEVIN

Attorney of Record

Michael D. Sydow

Age Healthier....Live
Happier!

Print: Jan 20, 2015

85744732

DESIGN MARK

Serial Number

85744732

Status

REGISTERED

Word Mark

POWERING PEOPLE WITH PELLETS

Standard Character Mark

Yes

Registration Number

4541541

Date Registered

2014/06/03

Type of Mark

TRADEMARK; SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(4) STANDARD CHARACTER MARK

Owner

bioTEmedical, Inc. CORPORATION NEVADA 800 W. Arbrook, Suite 100
Arlington TEXAS 76015

Goods/Services

Class Status -- ACTIVE. IC 005. US 006 018 044 046 051 052. G & S: Hormone replacement therapy preparations; Hormones; Hormones for medical purposes; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis. First Use: 2012/09/30. First Use In Commerce: 2012/09/30.

Goods/Services

Class Status -- ACTIVE. IC 041. US 100 101 107. G & S: Medical training and teaching. First Use: 2012/09/30. First Use In Commerce: 2012/09/30.

Print: Jan 20, 2015

85744732

Goods/Services

Class Status -- ACTIVE. IC 044. US 100 101. G & S: Consulting services in the field of hormone replacement therapy; Medical and pharmaceutical consultation; Medical clinic providing weight loss solutions, services and programs, nutrition counseling, hormone therapy, including, bioidentical hormone replacement, anti aging therapy, and natural hormone therapy, medical aesthetic procedures, including, laser hair removal, laser peels, botulinum toxin treatments, microdermabrasion, liposuction, vein treatments, vein therapy, cellulite treatments, body contouring treatments, injectable filler treatments, facials, and skin care. First Use: 2012/09/30. First Use In Commerce: 2012/09/30.

Filing Date

2012/10/03

Examining Attorney

DINALLO, KEVIN

Attorney of Record

Michael D. Sydow

Powering People With Pellets!

Print: Jan 20, 2015

86252979

DESIGN MARK

Serial Number

86252979

Status

REGISTERED

Word Mark

BLOOM

Standard Character Mark

No

Registration Number

4641014

Date Registered

2014/11/18

Type of Mark

TRADEMARK; SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(5) WORDS, LETTERS, AND/OR NUMBERS IN STYLIZED FORM

Owner

Amanda Ward INDIVIDUAL UNITED STATES 264 N. Coast Highway 101
Encinitas CALIFORNIA 92024

Goods/Services

Class Status -- ACTIVE. IC 003. US 001 004 006 050 051 052. G & S:
Body and beauty care cosmetics; Cosmetic creams; Cosmetic creams for
skin care; Cosmetic hand creams; Cosmetic nourishing creams; Cosmetic
oils; Cosmetic preparations; Cosmetic preparations against sunburn;
Cosmetic preparations for body care; Cosmetic preparations for
protecting the skin from the sun's rays; Cosmetic preparations for
skin care; Cosmetic sun-protecting preparations; Cosmetic sunscreen
preparations; Cosmetics; Lotions for cosmetic purposes; Oils for
cosmetic purposes; Skin and body topical lotions, creams and oils for
cosmetic use; Wrinkle-minimizing cosmetic preparations for topical
facial use. First Use: 2009/05/11. First Use In Commerce:
2009/05/11.

Goods/Services

Class Status -- ACTIVE. IC 005. US 006 018 044 046 051 052. G & S:
Chocolate-based meal replacement bars for treating cortisol imbalances
that cause weight gain; Chocolate-based meal replacement bars

Print: Jan 20, 2015**86252979**

for medical purposes; Dermatological pharmaceutical products; Dietary and nutritional supplements; Dietary and nutritional supplements for endurance sports; Dietary and nutritional supplements used for weight loss; Digestives for pharmaceutical purposes; Fruit-based meal replacement bars for medical purposes; Fruit-based meal replacement bars for treating vitamin B12 deficiency that causes fatigue; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Liquid nutritional supplement; Medicated cosmetics; Mineral nutritional supplements; Nutritional and dietary supplements formed and packaged as bars; Nutritional supplement energy bars; Nutritional supplement for eliminating toxins from the body; Nutritional supplement for eliminating toxins from the intestinal tract; Nutritional supplement in the nature of a nutrient-dense, protein-based drink mix; Nutritional supplement meal replacement bars for boosting energy; Nutritional supplement shakes; Nutritional supplements; Nutritional supplements, namely, probiotic compositions; Pharmaceutical agents for epidermis; Pharmaceutical preparation for skin care; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Plant and herb extracts sold as components of medicated cosmetics; Plant extracts for medical, veterinary and pharmaceutical purposes; Powdered nutritional supplement concentrate; Powdered nutritional supplement drink mix; Sunburn preparations for pharmaceutical purposes; Syringes sold filled with liquid vitamins and homeopathic treatments; Vitamin and mineral formed and packaged as bars. First Use: 2009/05/11. First Use In Commerce: 2009/05/11.

Goods/Services

Class Status -- ACTIVE. IC 025. US 022 039. G & S: Tops; Women's clothing, namely, shirts, dresses, skirts, blouses. First Use;

Print: Jan 20, 2015

86252979

2009/05/11. First Use In Commerce: 2009/05/11.

Goods/Services

Class Status -- ACTIVE. IC 032. US 045 046 048. G & S: Aloe juice beverages; Apple juice beverages; Aromatized beverages based on fruit, protein, cordial, sugar and other fluid nutrients, namely, carbohydrates drinks for use as food fillers; Aromatized beverages based on fruit, protein, cordial, sugar and other fluid nutrients, namely, protein drinks for use as food fillers and not for use as meal replacements; Beauty beverages, namely, fruit juices and energy drinks containing nutritional supplements; Frozen fruit drinks; Fruit beverages; Fruit drinks; Fruit drinks and fruit juices; Fruit drinks and juices; Fruit flavored drinks; Fruit flavored soft drinks; Fruit flavoured carbonated drinks; Fruit flavoured drinks; Fruit juice; Fruit juices and fruit drinks; Fruit-flavored beverages; Smoothies; Vegetable juice; Vegetable juices. First Use: 2009/05/11. First Use In Commerce: 2009/05/11.

Goods/Services

Class Status -- ACTIVE. IC 043. US 100 101. G & S: Coffee and juice bar services; Juice bar services; Preparation of food and beverages; Providing of food and drink; Providing of food and drink for patients and guests. First Use: 2009/05/11. First Use In Commerce: 2009/05/11.

Goods/Services

Class Status -- ACTIVE. IC 044. US 100 101. G & S: Conducting medical examinations for insurance purposes; Conducting medical physical evaluations; Consulting services in the field of medical care; DNA screening for medical purposes; Genetic testing for medical purposes; Medical and pharmaceutical consultation; Medical clinic providing weight loss solutions, services and programs, nutrition counseling, hormone therapy, including, bioidentical hormone replacement, anti aging therapy, and natural hormone therapy, medical aesthetic procedures, including, laser hair removal, laser peels, botulinum toxin treatments, microdermabrasion, liposuction, vein treatments, vein therapy, cellulite treatments, body contouring treatments, injectable filler treatments, facials, and skin care; Medical clinics; Medical consultations; Medical screening; Medical services; Medical skin care services; Medical testing for diagnostic or treatment purposes; Medical testing of urine, blood, hair follicles and breath; Medical, hygienic and beauty care; Non-invasive cosmetic medical procedures. First Use: 2000/05/11. First Use In Commerce: 2009/05/11.

Description of Mark

The mark consists of Pink cursive "BLOOM" logo with small green leaf extending from "M". The color white is employed merely as background.

Colors Claimed

Print: Jan 20, 2015

86252979

The color(s) pink and green is/are claimed as a feature of the mark.

Filing Date


2014/04/15

Examining Attorney

SALEMI, DOMINICK

bloom.


http://www.abbott.com/our-products.html 01/20/2015 11:11:58 AM

 [LIVE HEALTHY](#) [GET INSPIRED](#) [FOR PROFESSIONALS](#) [SEARCH](#)





[OUR PRODUCTS](#) [CAREERS](#) [CITIZENSHIP](#) [INVESTORS](#) [NEWSROOM](#) [PARTNERS](#) [ABOUT ABBOTT](#)

OUR PRODUCTS

VIEW A SELECTION OF THE PRODUCTS THAT OVER ONE MILLION PEOPLE USE EVERY DAY.



FEATURED BRANDS

<http://www.abbott.com/our-products.html> 01/20/2015 11:11:58 AM

Similac

A complete line of infant formulas to give babies the strongest possible start.

Similac

Complete, balanced nutrition and delicious flavors for kids on the go.

PediaLyte

Specially formulated to help prevent dehydration by restoring minerals and nutrients lost during diarrhea and vomiting.

Licorice

Nutritionally complete, amino acid-based medical food and infant formula with iron.

blink
drops

Uniquely formulated lubricating drops that provide dry eye relief with every blink.

Revitalens

Advanced technology that takes contact lens discomfort to a higher level.

ZONE
Performance

Nutrition for busy people who refuse to sacrifice great taste.

EAS
SPORTS NUTRITION

Science-based nutrition to help keep you healthy, active and ready for any challenge.

Ensure

Complete nutrition products designed to support your active lifestyle.

FreeStyle

Designed to make monitoring glucose levels and managing diabetes easier and more convenient.

Glucerna

Specialized nutrition to help maintain healthy blood glucose levels and manage diabetes.

AlphaTrak
MONITORING SYSTEM

A simple, accurate way to monitor and manage your diabetic pet's blood glucose levels from the comfort of home.

MORE BRANDS

Nutrition

+

Diagnostics

+

Vascular

+

Vision Care +

Diabetes Care +

Animal Health +

Pharmaceuticals -

A

Adomet (S-adenosyl-L-methionine)

B

Biaxin (clarithromycin)

Biaxin XL (clarithromycin extended-release)

Brufen (ibuprofen)

C

Creon (pancreatin)

D

Dicetel (pinaverium bromide)

Donamet (S-adenosyl-L-methionine)

Duphalac (lactulose)

Duphaston (dydrogesterone)

Duspatal (mebeverine)

F

Femoston (17 beta-estradiol/dydrogesterone)

H

Heptral (S-adenosyl-L-methionine)

I

Influvac (seasonal vaccine)

K

Klacid (clarithromycin)

Klaricid (clarithromycin)

Klaricid OD (clarithromycin extended-release)

L

Lipanthyl (fenofibrate)

Luvox (fluvoxamine)

O

Omacor (omega-3-acid ethyl esters 90)

S

Samyr (S-adenosyl-L-methionine)

Serc (betahistine)

Synthroid (levothyroxine sodium)

T

Tarka (ACE inhibitor + CCB)

Teveten (angiotensin receptor antagonist)

Transmetil (S-adenosyl-L-methionine)

Tricor (fenofibrate)

http://www.abbott.com/our-products.html 01/20/2015 11:11:58 AM

PRODUCT RESOURCES

[MSDS](#) 

[PATENTS](#) 

[GLOBAL PRODUCT PROTECTION](#) 



MAKING AN EVERLASTING
IMPACT ON HUMAN
HEALTH FOR 125 YEARS.

[LIVE HEALTHY
GET INSPIRED
FOR
PROFESSIONALS](#)

[PRODUCTS
CAREERS
CITIZENSHIP
INVESTORS
NEWSROOM
PARTNERS
ABOUT ABBOTT](#)


[SITE MAP
POLICIES
CONTACT
GLOBAL SITES
PRIVACY POLICY
TERMS &
CONDITIONS](#)

[FACEBOOK
TWITTER
INSTAGRAM
YOUTUBE](#)


© 2015 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

<http://www.abbott.com/live-healthy.html> 01/20/2015 11:13:29 AM


 [LIVE HEALTHY](#) [GET INSPIRED](#) [FOR PROFESSIONALS](#) [SEARCH](#)

[THRIVE](#) [KNOW](#) [MANAGE](#)



LIVE HEALTHY

STRIVE TO BE HEALTHIER AND MORE VITAL.




THRIVE


BE EXTRAORDINARY IN ALL THAT YOU DO.

Discover expert advice, tips and resources to help you achieve better health through every life stage.


<http://www.abbott.com/live-healthy.html> 01/20/2015 11:13:29 AM



http://www.abott.com/live-healthy.html 01/20/2015 11:13:29 AM



MANAGE




ACCEPT NO LIMITS TO YOUR POTENTIAL.

Learn ways to better manage health-related challenges and take charge of your wellness.

EXPLORE

HEART HEALTH DIABETES EYE HEALTH


 **Abbott**

MAKING AN EVERLASTING
IMPACT ON HUMAN
HEALTH FOR 125 YEARS.

| | | | |
|---------------|--------------|----------------|-----------|
| LIVE HEALTHY | PRODUCTS | SITE MAP | FACEBOOK |
| GET INSPIRED | CAREERS | POLICIES | TWITTER |
| FOR | CITIZENSHIP | CONTACT | INSTAGRAM |
| PROFESSIONALS | INVESTORS | GLOBAL SITES | YOUTUBE |
| | NEWSROOM | PRIVACY POLICY | |
| | PARTNERS | TERMS & | |
| | ABOUT ABBOTT | CONDITIONS | |

© 2015 Abbott. All Rights Reserved. Please read the Legal Notice for further details.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.


<http://www.abbott.com/for-professionals.html> 01/20/2015 11:13:53 AM



<http://www.abbott.com/for-professionals.html> 01/20/2015 11:13:53 AM

OUR BUSINESSES

| | | | |
|--|--|---|---|
| NUTRITION Discover our world-class nutrition science, research and product development. | DIAGNOSTICS Learn how our products transform medical diagnosis from an art to a science. | VASCULAR Find out how our vascular line lays the foundation for better health outcomes. | VISION CARE See how we are advancing vision technology with lasers for vision correction. |
| DIABETES CARE See our new products and state-of-the-art software offerings in diabetes care. | ANIMAL HEALTH Explore our products aimed at improving the lives of animals. | PHARMACEUTICALS Learn about our broad portfolio of high quality, trusted pharmaceutical brands. | |

 **OUR PRODUCTS**
EXPLORE PRODUCTS

Learn more about our groundbreaking products designed to help people stay strong and healthy in all stages of life.

SOLUTIONS

NURTURING HEALTH AT EVERY STAGE

For more than 125 years, we've been committed to helping people reach their potential through better health. With a diverse portfolio of nutrition solutions, diagnostics, medical devices and pharmaceuticals, we offer you the tools to help give children what they need to grow and adults what they need to thrive so we can all be our best across all aspects and stages of life.

Good nutrition is one of the best ways to ensure good health at every stage. Our broad range of nutrition solutions are designed to meet distinct nutrition needs from infancy through adulthood and old age. Access to the right information is one key to maximizing health. Our diagnostic solutions are engineered to deliver accurate, timely and personalized data to help you make better treatment decisions. Our medical devices—from glucose monitoring systems to vascular devices—push the boundaries of technology and innovation to help manage and treat some of life's greatest health challenges. And, our proven pharmaceutical products provide high-quality, trusted, branded generic medicines to help meet the needs of people around the world, in both developed and emerging markets outside the United States.

INNOVATION

MAKING A DIFFERENCE, ONE DISCOVERY AT A TIME

Whether exploring a promising new therapy, rethinking an age-old public health question or preventing a disease before it starts, we challenge ourselves to push the limits of science and technology. For over a century, we've dedicated ourselves to developing new solutions to some of the world's most complicated health issues to help make life better for people around the world. This passion drives us to innovate in everything we do—from research and development to manufacturing and logistics. But no matter how much we accomplish, we relentlessly strive to do even more. Because we know that what we accomplish today is our inspiration for what we can achieve tomorrow.

COMMITMENT

ACHIEVING BETTER

HEALTH, TOGETHER

Making a lasting impact on the health of the world requires a holistic view. It requires looking at a health challenge from all angles—including prevention, diagnosis, treatment, management, access, education and information. And then collaborating with some of the greatest minds in science, medicine and health to bring forth the right solutions for the people we serve. As your partner, we know this demands more of us. It's not just developing innovative products and services, but providing better access to essential medicines and services, partnering to advance patient awareness and education, and collaborating with local experts and organizations to provide customized solutions for the communities that need it most. By working together, we can realize better health outcomes for people at every stage of life, in every corner of the world.



MAKING AN EVERLASTING
IMPACT ON HUMAN
HEALTH FOR 125 YEARS.

LIVE HEALTHY
GET INSPIRED
FOR
PROFESSIONALS

PRODUCTS
CAREERS
CITIZENSHIP
INVESTORS
NEWSROOM
PARTNERS
ABOUT ABBOTT

SITE MAP
POLICIES
CONTACT
GLOBAL SITES
PRIVACY POLICY
TERMS &
CONDITIONS


FACEBOOK
TWITTER
INSTAGRAM
YOUTUBE

© 2015 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

[more >>](#)

<http://www.bayerpharma.com/en/therapeutic-areas/therapeutic-areas-a-z/contraception.php>
01/20/2015 11:22:01 AM



Oral contraceptives

When people talk about oral contraceptives, or the "pill", they usually mean the combined pill which contains an estrogen and a progestin. The progestin exerts the actual contraceptive effect while the estrogen maintains a regular menstrual cycle. The combined pill is the most commonly used form of hormonal contraception.

More information on oral contraceptives

- » Safety
- » Side effects
- » Thrombosis / Embolism

Drospirenone-containing combined pills

Combined pills are available with various types of progestins. Some progestins have certain effects in addition to contraception, for example the progestin drospirenone, which closely resembles the natural progesterone produced by a woman's body. Thanks to its properties, drospirenone counteracts estrogen-induced water retention and its related symptoms. Drospirenone-containing pills are the most widely prescribed hormonal contraceptives in the world today.

A low-dose drospirenone-containing pill with an administration regimen in which hormone-containing tablets are taken for 24 days, followed by only 4 days of tablets with no active ingredient, is available in major markets worldwide. Due to the special properties of drospirenone and the advantages of this administration regimen, the product reduces the typical hormonal fluctuations and potentially related symptoms which often occur with the conventional 21/7 pill. (The conventional 21/7 regimen consist of 21 days of active pills, followed by a 7-day pill-free interval.) The pill has been approved in several countries throughout the world, including the U.S., for three indications: oral contraception, the treatment of moderate acne, and the treatment of emotional and physical symptoms of Premenstrual Dysphoric Disorder (PMDD), the most severe form of

<http://www.bayerpharma.com/en/therapeutic-areas/therapeutic-areas-a-z/contraception.php>
01/20/2015 11:22:01 AM

but not the combined oral contraceptive pill. The combined oral contraceptive pill is not recommended for women with premenstrual syndrome (PMS).

In addition there are birth control pills that also provide a daily dose of folate, a B vitamin. It is well established that folates play an important role during the first weeks of pregnancy. Folate is an essential nutrient that many women of childbearing age lack. A well-established body of evidence supports folate supplementation as a means to reduce the incidence of neural tube defects – or birth defects of the brain and spinal cord. Folate supplementation is particularly important at least one month before and three months after conception. Women who discontinue their pill or do not take them correctly may become pregnant before seeking preconception counseling from their healthcare provider, and combining an oral contraceptive with folate targets to reduce the risk of neural tube defects. These combined oral contraceptives have been developed in two regimens – 24/4 (consisting of 24 days of hormone-containing tablet with folate followed by four days of folate only) and 21/7 (consisting of 21 days of hormone-containing tablets with folate followed by seven days of folate only). They are approved in the US and several other countries in the world.

Furthermore a low-dose drospirenone-containing pill with a flexible extended regimen is being offered. This provides the option of 'personal period planning'. The number and timing of periods can be chosen within the limits permitted by the approved dosing regimen. The flexible dosing regimen involves a daily intake for a minimum period of 24 days and up to a maximum period of 120 days. During day 26 to 120, a 4-day tablet-free interval individually can be scheduled which triggers the period. This offers the option of flexibly reducing the number of periods to three per year. An innovative digital tablet dispenser supports the new regimen and reminds when to take the pill.

The combined pill based on estradiol

Over the past 50 years, many new progestins have been developed for use in oral contraceptives, but the estrogen component remained the same – ethinylestradiol. However, an oral contraceptive has been available since May 2009 where its estrogen component differs from that of virtually all other oral contraceptives. This pill contains estradiol valerate which is immediately metabolized to estradiol, the same estrogen as produced by the female body.

This pill combines estradiol valerate with the progestin dienogest in a dosing regimen in which the estrogen component is gradually reduced and the progestin component gradually increased over a total of 26 days (the tablets for 2 days contain no active substance). The aim of this dosing regimen is to achieve a balance between the estrogen and progestin components and to ensure reliable contraceptive protection and good cycle control in harmony with the woman's body.

Contraception using the intrauterine systems

The intrauterine system (IUS) consists of a flexible plastic T-shaped frame surrounded by a hormone cylinder which gradually releases a constant, small quantity of the hormone levonorgestrel (LNG). The IUS is placed directly into the womb by a clinician and can remain there up to three or to five years depending on the inserted IUS. The presence of the IUS is not felt. It can be easily removed by a clinician at any time and the woman's usual level of fertility return after removal.

The contraceptive effect provided by the IUS differs from that of oral contraceptives. The female hormonal cycle and the ovulation process remain virtually unchanged. The mode of action is based to a large extent on the local effects of the hormone. The IUS causes the viscosity of the cervical mucus to increase, and the cervix thus becomes impenetrable to sperms, which are then unable to reach the uterus.

<http://www.bayerpharma.com/en/therapeutic-areas/therapeutic-areas-a-z/contraception.php>
01/20/2015 11:22:01 AM

Permanent Contraception

When women conclude their family planning, it doesn't mean that their contraception ends as well – after all, women can become pregnant until the menopause. Bayer HealthCare Pharmaceuticals is now offering a non-incisional procedure for permanent contraception to ensure that women don't have to constantly think about contraceptive methods.

The gynecologist carries out the sterilization procedure either at the hospital or in his or her own office – and most women can go home after the procedure. In this method, the doctor inserts flexible microcoils into both fallopian tubes via a hysteroscope after application of local anesthesia. Over the next three months, tissue forms around the microcoil and creates a natural barrier within fallopian tubes, and prevents sperm from reaching the eggs. To find out if this method is suitable for a woman, she should consult her healthcare professional.

Advice for patients

Everybody reacts differently to medicines. Therefore it is impossible to tell which medicine works best for you. Please consult your physician.

[» Overview Therapeutic Areas A-Z](#)


Share this:      AAA

Age-related macular degeneration (AMD) | Breast cancer | Central retinal vein occlusion (CRVO) | Colorectal Cancer (CRC) | Contraception | Diabetes | Epileptic muscular atrophy (EMA) | Endometriosis | Erectile dysfunction | Gastrointestinal stromal tumor (GIST) | Gynecological therapy | Heart attack | Heartstopper and stroke | Hemophilia | High blood pressure | Infectious diseases | Liver cancer | Menopausal complaints | Multiple sclerosis | Non-cystic fibrosis bronchiectasis (NCFB) | Peripheral arterial occlusive disease | Premenstrual dysphoric disorder (PMDD) | Prostate cancer | Pulmonary arterial hypertension | Renal cell carcinoma | Stroke | Testosterone deficiency | Thrombosis | Thoracic Cancer |

| Company | Therapeutic Areas | Research and Development | Partnering | Corporate Responsibility | Press |
|---------------------|-----------------------|--------------------------|------------------------|--------------------------|------------------|
| About us | Therapeutic Areas A-Z | Facts & Figures | Our Philosophy | Family Planning | Media contacts |
| Locations worldwide | Z | Research Focus | Bayer Partnering | Neglected diseases | In focus |
| History | Products | Processes | Team | Medical Care | Podcast Center |
| Public Policy | | Technologies & Trends | Our areas of interest | Partner | in dialog |
| Career | | Collaborations | Forms of Collaboration | Responsibility | BHC Press Portal |
| Code of Ethics | | Development Pipeline | Partnership with us | Environmental protection | |
| | | Clinical Trials | News | | |
| | | Ethics in R&D | Where to meet us | | |
| | | News | | | |

Last updated: 2014

Copyright © Bayer Pharma AG
Conditions of Use | Privacy Statement | Imprint



Bayer HealthCare: Science For A Better Life

Pharmaceuticals

Contact us | RSS | Search | Sitemap | Deutsch » Bayer Group

[Homepage](#)
[Company](#)
[Therapeutic Areas](#)
[Research and Development](#)
[Partnering](#)
[Corporate Responsibility](#)
[Press](#)

Therapeutic Areas A-Z

Products

Overview

Beware of Counterfeits

Patient and drug safety

Bayer Links

Bayer HealthCare Global Investor Relations

LINKS

Page tools

Country Links

Publications

- Bayer Annual Report 2013
- Stockholders' Newsletter for the third quarter 2013
- research - The Bayer Scientific Magazine

Annual Report 2013



Current Annual Report of Bayer AG »

120 years of experience

Our success is based on more than 120 years of experience. We focus on **researching and developing innovative medications** and new therapeutic approaches. At the same time, we continue to improve our established products.

more »

Products

The future of medicine lies in individual approaches and in building bridges between prevention, diagnosis and therapy. Bayer HealthCare Pharmaceuticals meets this challenge with proven, successful products based on many decades of knowledge and experience.

We offer prescription medicines for:

- Cardiovascular and blood diseases**
Heart attack, high blood pressure, peripheral arterial occlusive disease, pulmonary hypertension, stroke, thrombosis
- Oncological diseases:**
Breast cancer, liver cancer, non-Hodgkin lymphoma, prostate cancer, renal cell cancer
- Ophthalmology:**
Age-related macular degeneration (AMD)
- Women's healthcare:**
Hormonal contraception, endometriosis, gynecological diseases, menopausal complaints, premenstrual dysphoric disorder (PMDD)
- Other diseases:**
Diabetes, erectile dysfunction, hemophilia, infections, multiple sclerosis, testosterone deficiency

Information on prescription medicines

In European countries, we are only allowed to provide information on prescription medicines to health care professionals. For information on our prescription medicines, please consult your physician

» More information about our ten top-selling products

http://www.bayerpharma.com/en/therapeutic-areas/products/overview/index.php 01/20/2015 11:22:33 AM

Products

Click here for more information about this topic.

» [Browse all Counterfeits](#)

Share this:



Age-related macular degeneration (AMD) | Breast cancer | Central retinal vein occlusion (CRVO) | Colorectal Cancer (CRC) | Contraception | Diabetes | Diabetic macular edema (DME) | Endometriosis | Erectile dysfunction | Gastrointestinal stromal tumor (GIST) | Gynecological therapy | Heart attack | Heart attack and stroke | Hemophilia | High blood pressure | Infectious diseases | Liver cancer | Menopausal complaints | Multiple sclerosis | Non-cystic fibrosis bronchiectasis (NCFB) | Peripheral arterial occlusive disease | Pharyngeal dysphagia disorder (PDSD) | Prostate cancer | Pulmonary arterial hypertension | Renal cancer | Skin cancer | Stroke | Testosterone deficiency | Thrombosis | Thyroid Cancer |

| Company | Therapeutic Areas | Research and Development | Partnering | Corporate Responsibility | Press |
|---------------------|-----------------------|--------------------------|------------------------|--------------------------|------------------|
| About us | Therapeutic Areas A-Z | Facts & figures | Our Philosophy | Family History | Media contacts |
| Locations worldwide | Products | Research Focus | Bayer Partnering Team | Neglected diseases | Infocus |
| History | | Processes | Our areas of interest | Medical Care | Podcast Center |
| Public Policy | | Technologies & Trends | Forms of Collaboration | Partner | In dialog |
| Career | | Collaborations | Partnering with us | Responsibility | BHC Press Portal |
| Code of Ethics | | Development Pipeline | News | Environmental protection | |
| | | Clinical Trials | Where to meet us | | |
| | | Ethics in R&D | | | |
| | | News | | | |

Last updated: 2018

Copyright © Bayer Pharma AG
Conditions of Use | Privacy Statement | Imprint

http://www.roche.com/about/personalised_healthcare.htm 01/20/2015 11:28:21 AM

Global Web Site [Roche in your country](#) [Deutsch](#) [Contact](#)


[Home](#) [About Roche](#) [Products](#) [Sustainability](#) [Research & Development](#) [Media](#) [Investors](#) [Careers](#)

[About Roche](#) > [Personalised Healthcare](#)

Personalised Healthcare (PHC)


Patients are different and so is their treatment

Find out what PHC is




[Share](#) [Rate](#)


PHC at Roche



Roche Personalised Healthcare - our structure
[watch video](#)



Roche Personalised Healthcare - our mission
[watch video](#)



Now Roche is making personalised healthcare a reality

http://www.roche.com/about/personalised_healthcare.htm 01/20/2015 11:28:21 AM

Personalised Healthcare



How Personalised Healthcare works
[watch video](#)

Personalised Healthcare



Advantages of Personalised Healthcare
[watch video](#)

Personalised Healthcare



Personalised Healthcare
[watch video](#)

Progress



Understanding disease mechanism leads to targeted therapies
[watch video](#)



Personalised Healthcare-the economists' perspective
[watch video](#)

Cancer



http://www.roche.com/about/personalised_healthcare.htm 01/20/2015 11:28:21 AM



From precise diagnosis to more personalised therapy
[watch video](#)



Intervening at the molecular level
[watch video](#)



Using personalised healthcare to treat metastatic melanoma (skin cancer)
[watch video](#)


Hepatitis



New therapies for patients
[watch video](#)



The perspective of hepatitis C patient Kiyotaka Hirose (Japan)
[watch video](#)



Personalised treatment strategies
[watch video](#)



Personalised Healthcare - example Hepatitis
[watch video](#)

© 2015 F. Hoffmann-La Roche Ltd. 20.01.2015 [Legal Statement](#) [Privacy Policy](#)

[Find us](#)

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.


http://www.roche.com/research_and_development.htm 01/20/2015 11:28:50 AM

Global Web Site [Roche in your country](#) [Deutsch](#) [Contact](#)


[Home](#)
[About Roche](#)
[Products](#)
[Sustainability](#)
[Research & Development](#)
[Media](#)
[Investors](#)
[Careers](#)

Research & Development

Scientific breakthroughs are most likely to occur when scientists are free to tackle problems from different angles and in different ways. Our scientists have this freedom.




What we are working on



the heart of what we do. Our ideas and research help save lives.
[more](#)

Who we are and how we work



come to work each day to develop medical innovations.
[more](#)

Be part of our community

Latest jobs

Praktikum im Global Market Access [Deutschland, Mannheim](#)

Analytik Laborant (m/w) im Entwicklungsab. (temporär für 2 Jahre) [Schweiz, Basel](#)

Chemikant/Produktionsangestellter (m/w) [Quebec, Quebec Ville](#)

Chemiewerker (m/w) [Deutschland, Penzberg](#)

Genovese, Carrie
lunch tomorrow
It's finally happening!
Same game? I haven't been to Kuroba in like six months.

http://www.roche.com/research_and_development.htm 01/20/2015 11:28:50 AM

What type of researcher are you?



Take the quiz!
[more](#)

Latest news

13 January 2015
Roche, Meiji Seika Pharma (Meiji) and Federa join forces to tackle increasing bacterial resistance to antibiotics
Roche, Meiji Seika Pharma (Meiji) and Federa announced today that they have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor in phase I clinical development.
[more](#)

12 January 2015
Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology

Roche and Foundation Medicine, Inc. announced today that they will enter into a broad strategic collaboration to further advance FMI's market-leading position in molecular information and genomic analysis while providing Roche a unique opportunity to optimize the identification and development of novel treatment options for cancer patients.
[more](#)

9 January 2015
FDA Approves Roche's Blood Screening Assay for Simultaneous Detection and Identification of Three Major Viral Targets
[more](#)

Roche Partnering



At Roche Partnering, we are passionate about science: yours and ours. Through partnerships, we hope that together we can build a better future with medicines that make a real difference to patients.

Eight steps from idea to medicine



See what it takes to create a new medicine. The path is long, arduous and fraught with risk. But the results can improve and extend lives.
[more](#)

By the numbers



Go inside a lab where new medicines are made



Our research teams test thousands of compounds in the search for a new medicine. It takes many years and an investment of millions of Swiss francs. This lab in Basel is


Genovese, Carrie
lunch tomorrow!
it's finally happening!
Same same? I haven't been to Kuzbro in like six months.

Genovese, Carrie
lunch tomorrow!
it's finally happening!
Same same? I haven't been to Kuzbro in like six months.

http://www.roche.com/research_and_development.htm 01/20/2015 11:28:50 AM

[more](#)

How we structure R&D



To ensure a strong pipeline, we have built a network of R&D centers around the world.


[more](#)

By the numbers

18,279

people employed in R&D in 2012.

Pipeline




[more](#)

Get up-to-date information about our Pharma and Diagnostics pipeline.

[more](#)


Value of innovation



Explore our innovation stories, where we show you some of the ways we are helping to improve healthcare delivery.

[more](#)

Personalised Healthcare



Working in both Pharmaceuticals and Diagnostics, we are uniquely positioned to fit the treatment to the patients.

[more](#)

By the numbers

8.7

billion Swiss Francs spent on R&D in 2013.

© 2015 F. Hoffmann-La Roche Ltd 2015 Legal Statement Privacy Policy

[Find us](#)

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

investment of millions of Swiss francs. This lab in Basel is one of the first stages in that long journey.

[explore our lab](#)

Genovese, Carrie
lunch tomorrow!
It's finally happening!
Some, some? I haven't been to Rustico in like six months.

Genovese, Carrie
lunch tomorrow!
It's finally happening!
Some, some? I haven't been to Rustico in like six months.

Genovese, Carrie
lunch tomorrow!
It's finally happening!
Some, some? I haven't been to Rustico in like six months.

<http://www.roche.com/products/product-list.htm?region=us&type=divpharma&id=Pharmaceuticals>
01/20/2015 11:29:19 AM

Global Web Site

[Roche in your country](#)

[Deutsch](#)

[Contact](#)

[Home](#)

[About Roche](#)

Products

[Sustainability](#)

[Research & Development](#)

[Media](#)

[Investors](#)

[Careers](#)

Products > Product list

Pharmaceuticals available in the US

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A

AC TEMRA

Avastin

B

Boniva / Boniva

C

CellCept

F

Fuzeon

H

Herceptin

I

Invirase

Our US product portfolio

Products A-Z

Diseases

Products for Researchers

Solutions for Diagnostics

Our portfolio for non-US visitors

<http://www.roche.com/products/product-list.htm?region=us&type=divpharma&id=Pharmaceuticals>
01/20/2015 11:28:19 AM

K

Kytrol (Kevitrol)

L

Lucanis

P

Pegasys

Pulmozyme

T

Tamiflu

Tarceva

V

Valsyte

X

Xeloda

Xenical

Share

© 2015 F. Hoffmann-La Roche Ltd 20/01/2015 Legal Statement Privacy Policy

Find us

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

Print: Jan 20, 2015

75418921

DESIGN MARK

Serial Number

75418921

Status

REGISTERED AND RENEWED

Word Mark

WEBMD

Standard Character Mark

No

Registration Number

2349285

Date Registered

2000/05/16

Type of Mark

SERVICE MARK

Register

PRINCIPAL

Mark Drawing Code

(1) TYPED DRAWING

Owner

WEBMD LLC LIMITED LIABILITY COMPANY DELAWARE 111 EIGHTH AVENUE,
SEVENTH FLOOR NEW YORK NEW YORK 10011

Goods/Services

Class Status -- ACTIVE. IC 042. US 100 101. G & S: computer services, namely, providing medical information by way of a World Wide Web page accessible via global computer network. First Use: 1997/12/15. First Use In Commerce: 1998/01/07.

Filing Date

1998/01/16

Examining Attorney

MADDEN, ANNE

Attorney of Record

Michael J. Bevilacqua, Esquire

WEBMD

To: Calico LLC (tmdocketing@google.com)
Subject: U.S. TRADEMARK APPLICATION NO. 86220187 - CALICO - N/A
Sent: 1/20/2015 11:59:10 AM
Sent As: ECOM115@USPTO.GOV
Attachments:

UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO)

**IMPORTANT NOTICE REGARDING YOUR
U.S. TRADEMARK APPLICATION**

USPTO OFFICE ACTION (OFFICIAL LETTER) HAS ISSUED
ON **1/20/2015** FOR U.S. APPLICATION SERIAL NO. 86220187

Please follow the instructions below:

(1) TO READ THE LETTER: Click on this [link](#) or go to <http://tsdr.uspto.gov>, enter the U.S. application serial number, and click on “Documents.”

The Office action may not be immediately viewable, to allow for necessary system updates of the application, but will be available within 24 hours of this e-mail notification.

(2) TIMELY RESPONSE IS REQUIRED: Please carefully review the Office action to determine (1) how to respond, and (2) the applicable response time period. Your response deadline will be calculated from **1/20/2015** (*or sooner if specified in the Office action*). For information regarding response time periods, see <http://www.uspto.gov/trademarks/process/status/responsetime.jsp>.

Do NOT hit “Reply” to this e-mail notification, or otherwise e-mail your response because the USPTO does NOT accept e-mails as responses to Office actions. Instead, the USPTO recommends that you respond online using the Trademark Electronic Application System (TEAS) response form located at http://www.uspto.gov/trademarks/teas/response_forms.jsp.

(3) QUESTIONS: For questions about the contents of the Office action itself, please contact the assigned trademark examining attorney. For *technical* assistance in accessing or viewing the Office action in the Trademark Status and Document Retrieval (TSDR) system, please e-mail TSDR@uspto.gov.

WARNING

Failure to file the required response by the applicable response deadline will result in the ABANDONMENT of your application. For more information regarding abandonment, see

<http://www.uspto.gov/trademarks/basics/abandon.jsp>.

PRIVATE COMPANY SOLICITATIONS REGARDING YOUR APPLICATION: Private companies **not** associated with the USPTO are using information provided in trademark applications to mail or e-mail trademark-related solicitations. These companies often use names that closely resemble the USPTO and their solicitations may look like an official government document. Many solicitations require that you pay “fees.”

Please carefully review all correspondence you receive regarding this application to make sure that you are responding to an official document from the USPTO rather than a private company solicitation. All official USPTO correspondence will be mailed only from the “United States Patent and Trademark Office” in Alexandria, VA; or sent by e-mail from the domain “@uspto.gov.” For more information on how to handle private company solicitations, see http://www.uspto.gov/trademarks/solicitation_warnings.jsp.